$123 Million is the total value of Casdin Capital, LLC's 26 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 48.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $14,919,000 | +89.9% | 282,443 | +50.6% | 12.08% | +54.5% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $12,272,000 | +78.2% | 266,500 | +16.6% | 9.94% | +45.0% |
| FMI | Buy | FOUNDATION MEDICINE INC | $9,690,000 | +33.2% | 415,000 | +6.4% | 7.85% | +8.3% |
| EVH | Buy | EVOLENT HEALTH INCcl a | $9,479,000 | +106.2% | 385,000 | +60.8% | 7.68% | +67.7% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $8,524,000 | +23.8% | 287,000 | -15.6% | 6.90% | +0.7% |
| LOXO | Sell | LOXO ONCOLOGY INC | $7,618,000 | +9.5% | 291,000 | -3.0% | 6.17% | -10.9% |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $7,375,000 | +104.2% | 625,000 | +50.6% | 5.97% | +66.2% |
| ONCE | Sell | SPARK THERAPEUTICS INC | $5,616,000 | -32.4% | 93,500 | -42.5% | 4.55% | -45.0% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $5,532,000 | -22.5% | 240,000 | -44.2% | 4.48% | -36.9% |
| KITE | Buy | KITE PHARMA INC | $5,027,000 | +38.7% | 90,000 | +24.1% | 4.07% | +12.8% |
| BLUE | Sell | BLUEBIRD BIO INC | $4,067,000 | -23.3% | 60,000 | -51.0% | 3.29% | -37.6% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $3,966,000 | +92.7% | 110,000 | -26.7% | 3.21% | +56.8% |
| VYGR | Sell | VOYAGER THERAPEUTICS INC | $3,321,000 | -6.3% | 276,500 | -14.3% | 2.69% | -23.8% |
| EPZM | Sell | EPIZYME INC | $2,903,000 | -16.6% | 295,000 | -13.2% | 2.35% | -32.2% |
| EXAS | New | EXACT SCIENCES CORP | $2,878,000 | – | 155,000 | +100.0% | 2.33% | – |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $2,643,000 | -34.3% | 39,000 | -46.2% | 2.14% | -46.6% |
| MDRX | New | ALLSCRIPTS HEALTHCARE SOLUTN | $2,634,000 | – | 200,000 | +100.0% | 2.13% | – |
| MYOK | Sell | MYOKARDIA INC | $2,614,000 | +17.7% | 160,000 | -10.6% | 2.12% | -4.2% |
| GHDX | New | GENOMIC HEALTH INC | $2,603,000 | – | 90,000 | +100.0% | 2.11% | – |
| MDGN | Buy | MEDGENICS INC | $2,089,000 | +342.6% | 375,000 | +341.2% | 1.69% | +260.0% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $1,999,000 | -16.4% | 127,500 | -45.6% | 1.62% | -32.0% |
| IBB | New | ISHARES TRnasdq biotec etf | $1,447,000 | – | 5,000 | +100.0% | 1.17% | – |
| RXDX | Sell | IGNYTA INC | $1,227,000 | -39.6% | 195,000 | -48.0% | 0.99% | -50.9% |
| IONS | New | IONIS PHARMACEUTICALS INC | $1,209,000 | – | 33,000 | +100.0% | 0.98% | – |
| EDIT | New | EDITAS MEDICINE INC | $1,152,000 | – | 85,470 | +100.0% | 0.93% | – |
| SYRS | SYROS PHARMACEUTICALS INC | $694,000 | -23.6% | 50,000 | 0.0% | 0.56% | -37.8% | |
| DXCM | Exit | DEXCOM INC | $0 | – | -15,000 | -100.0% | -1.18% | – |
| DXCM | Exit | DEXCOM INCput | $0 | – | -15,000 | -100.0% | -1.18% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -21,000 | -100.0% | -1.54% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -30,000 | -100.0% | -1.61% | – |
| TSRO | Exit | TESARO INC | $0 | – | -20,000 | -100.0% | -1.67% | – |
| AVXS | Exit | AVEXIS INC | $0 | – | -45,000 | -100.0% | -1.70% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCcall | $0 | – | -65,000 | -100.0% | -1.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.